الفهرس | Only 14 pages are availabe for public view |
Abstract Introduction Bariatric surgery is the most effective treatment for patients with severe obesity (body mass index of Greater than or equal 40 kg/m2), both in terms of weight loss and improvements in obesity-related diseases such as Type 2 diabetes (T2D). The mechanisms underlying the beneficial effects of bariatric surgery are now the focus of a burgeoning field of research, with the aim of developing new therapies for obesity and T2D. In this regard, there has been an increasing interest in the role that gut hormones may play in mediating the physiological changes produced by certain bariatric procedures, such as sleeve gastrectomy and one anastomosis gastric bypass. Methods This is a Prospective comparative study that included 40 T2D patients. Patients were divided into two groups; 20 of them underwent sleeve gastrectomy, and the other 20 underwent one anastomosis gastric bypass, the selected patients were followed up. measuring fasting GLP-1 one day preoperative, three month and one year postoperative in both sleeve gastrectomy and one anastomosis gastric bypass. In addition to measuring HbA1c one day preoperative, three month and one year postoperative in both sleeve gastrectomy and one anastomosis gastric bypass. Initial weight & extent of weight loss were also measured. Results In our study, we found the following, first regarding percentage of excess weight loss (%EWL), in the sleeve gastrectomy group; we observed that there is a statistically significant increase in %EWL over a period of one year postoperatively (p value < 0.001), with a mean %EWL of 31.24% three months postoperatively and a mean %EWL of 58.95% one year postoperatively, While in the one anastomosis gastric bypass group; there is a statistically significant increase in the %EWL over a period of one year postoperatively (p value < 0.001), where the mean %EWL three months postoperatively was 31.73% with furthermore increase in %EWL one year postoperatively with a mean of 64.86%. second regarding glucagon like peptide 1 (GLP-1) In the sleeve gastrectomy subjects |